Prognosis:
Microprolactinomas have a good prognosis and prolactin levels normalize with treatment.
In macro prolactinoma, around 50% of patients are in remission after surgery.
Surgery/Radiation treatment:
Surgical treatment for prolactinomas are done when patients are resistant to medical therapy. Endoscopic endonasal transsphenoidal is the preferred method. Adjuvant radiation therapy should be considered for residual tumor.
Side effects of medications:
Nausea, vomiting, headache, constipation, dizziness, faintness, depression, postural hypotension, digital vasospasm and nasal stuffiness. All of the side effects, is mostly due to the lysergic acid part of the molecule.
Bromocriptine: This is a strong dopamine agonist which binds to dopamine receptor and directly inhibits PRL secretion. It acts by decreasing prolactin synthesis, DNA synthesis, cell multiplication and overall size of prolactinoma.
Once PRL levels reach to the normal levels, then check PRL levels after every 3 to 6 months in the first year and then after every 6 to 12 months.
Patients with visual disturbances should assessed by regular vision evaluation and MRI.
Radiological imaging can be repeated after 6-8 weeks of initiation of cabergoline therapy. On the other hand, in microprolactinoma, there is generally no need to repeat prolactin levels.
In macroprolactinoma: response to cabergoline therapy is generally relatively rapid (within weeks); normalisation (or drop) of prolactin levels provides a solid indication regarding therapeutic response.
In patients with a macroprolactinoma which shows growth during pregnancy, cabergoline can be initiated/continued. Cabergoline remains a safe option in pregnancy (especially from the 2nd trimester onwards) and should be tried even if the tumour shows signs of enlargement.
Cabergoline: Considered as the first line usually. This is more effective in suppressing prolactin and reducing tumor size.
Dose: 0.25mg twice per week, maximum dose of 1mg is given twice a week.
3. Hyperprolactinemia due to systemic disorders, drugs, pituitary hyper-secretion and hypothalamic-pituitary stalk damage: Treatment of underlying etiology
Management:
This can be divided into 3 groups:
1. Idiopathic or micro adenoma associated with hyperprolactinemia: Medical management is the mainstay.
2. Hyperprolactinemia with macroadenoma: Requires fertility management in combination of drugs and surgery/radiotherapy.
Serum prolactin levels are higher in the noon, so morning measurement is preferred. Hyperprolactinemia is defined as >20ng/mL in men and >25 ng/mL in women, measured at least 2 hours after waking. If levels not markedly raised, repeat testing is recommended before diagnosis.
it is important to recognize that the accuracy of MRI detection in microadenomas can vary based on several factors, as noted by Cano, A et al These include the magnetic field strength, the technique and time lapse between contrast administration and imaging data acquisition.
A pituitary microadenoma can be identified on MRI as:
T1 weighted images show microadenomas as isointense compared to surrounding normal pituitary. T2 weighted images may display a variable presentation.